



**HAL**  
open science

## Modulation of the immune response by the *Pseudomonas aeruginosa* type-III secretion system

Albane Jouault, Alessandra Mattos Saliba, Lhousseine Touqui

► **To cite this version:**

Albane Jouault, Alessandra Mattos Saliba, Lhousseine Touqui. Modulation of the immune response by the *Pseudomonas aeruginosa* type-III secretion system. *Frontiers in Cellular and Infection Microbiology*, 2022, 12, pp.1064010. 10.3389/fcimb.2022.1064010 . hal-04087236

**HAL Id: hal-04087236**

**<https://hal.sorbonne-universite.fr/hal-04087236v1>**

Submitted on 3 May 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



## OPEN ACCESS

## EDITED BY

Philippe Huber,  
Commissariat à l'Énergie Atomique et  
aux Énergies Alternatives (CEA), France

## REVIEWED BY

Jon Audia,  
University of South Alabama,  
United States  
Eric Faudry,  
CEA Grenoble, France

## \*CORRESPONDENCE

Albane Jouault  
albane.jouault@pasteur.fr

## SPECIALTY SECTION

This article was submitted to  
Molecular Bacterial Pathogenesis,  
a section of the journal  
Frontiers in Cellular and  
Infection Microbiology

RECEIVED 07 October 2022

ACCEPTED 15 November 2022

PUBLISHED 28 November 2022

## CITATION

Jouault A, Saliba AM and Touqui L  
(2022) Modulation of the immune  
response by the *Pseudomonas*  
*aeruginosa* type-III secretion system.  
*Front. Cell. Infect. Microbiol.*  
12:1064010.  
doi: 10.3389/fcimb.2022.1064010

## COPYRIGHT

© 2022 Jouault, Saliba and Touqui. This  
is an open-access article distributed  
under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#).  
The use, distribution or reproduction  
in other forums is permitted, provided  
the original author(s) and the  
copyright owner(s) are credited and  
that the original publication in this  
journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is  
permitted which does not comply with  
these terms.

# Modulation of the immune response by the *Pseudomonas aeruginosa* type-III secretion system

Albane Jouault<sup>1,2\*</sup>, Alessandra Mattos Saliba<sup>3</sup>  
and Lhousseine Touqui<sup>1,2</sup>

<sup>1</sup>Mucoviscidose: Phénotypique et Phénotypique, Centre de Recherche Saint-Antoine, Sorbonne  
Universités, UPMC Univ Paris 06, INSERM, Paris, France, <sup>2</sup>Département Santé Globale,  
Mucoviscidose et Bronchopathie Chroniques, Institut Pasteur, Paris, France, <sup>3</sup>Department of  
Microbiology, Immunology and Parasitology, Faculty of Medical Sciences, Rio de Janeiro State  
University, Rio de Janeiro, Brazil

*Pseudomonas aeruginosa* is an opportunistic pathogen that can cause critical cellular damage and subvert the immune response to promote its survival. Among the numerous virulence factors of *P. aeruginosa*, the type III secretion system (T3SS) is involved in host cell pathogenicity. Using a needle-like structure, T3SS detects eukaryotic cells and injects toxins directly into their cytosol, thus highlighting its ability to interfere with the host immune response. In this mini-review, we discuss how the T3SS and bacterial effectors secreted by this pathway not only activate the immune response but can also manipulate it to promote the establishment of *P. aeruginosa* infections.

## KEYWORDS

type-III secretion system, *Pseudomonas aeruginosa*, exotoxins, inflammation, pathogenicity

## Introduction

*Pseudomonas aeruginosa* is a Gram-negative bacterium causing infections in immunocompromised individuals. This pathogen is one of the ESKAPE pathogens (including *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *P. aeruginosa*, *Enterobacter* spp.), which constitute life-threatening nosocomial bacteria (Hirsch and Tam, 2010; Mulani et al., 2019). *P. aeruginosa* also infects patients with specific pathologies such as cystic fibrosis (CF). Due to its ability to form a biofilm, *P. aeruginosa* often chronically infects CF patients and represents a negative outcome in this disease (Malhotra et al., 2019).

To successfully establish itself in the host, *P. aeruginosa* deploys a series of virulence factors, including toxins, siderophores, adhesins, and secretion systems (see reviews of Gonçalves-de-Albuquerque et al., 2016; Qin et al., 2022). The latter allows the transport

of molecules into the extracellular media or host cells. Among the known secretion systems of *P. aeruginosa*, the type III secretion system (T3SS) is the most relevant in human pathogenesis and is implicated in host invasion by injecting toxins directly into eukaryotic cells (Hauser, 2009; Juan et al., 2017). It plays a significant role in the colonization of the host by *P. aeruginosa*, and several studies show a close relationship between T3SS expression and the modulation of the host immune system. This review aims to discuss the current knowledge regarding the interactions between T3SS and the host immune response.


## T3SS structure

The *P. aeruginosa* T3SS is a complex machinery that includes a needle complex, a translocon, effectors, chaperones, and a regulatory system (reviewed by Hauser, 2009; Horna and Ruiz, 2021).

The needle complex consists of a multi-ring base and a needle-like filament (Figure 1). The multi-ring base includes the PscC protein for the outer rings and the PscD and PscJ proteins for the inner ring (Notti and Stebbins, 2016). PscI connects the multi-ring base to the needle (Deng et al., 2017). The needle-like filament, composed of PscF subunits, allows the passage of effectors and serves as a sensor for host cell contact (Lombardi

et al., 2019). The translocon, composed of the PopB, PopD, and PcrV proteins, is also reported as the needle tip complex. PcrV is involved in the assembly of the PopB/D complex, which allows the injection of effectors into host cells by forming a pore in the host cell membrane (Goure et al., 2004; Romano et al., 2011). As such, the pore formed can lead to host cell death regardless of effector action (Audia et al., 2013).

Although PemA, PemB, and the nucleoside diphosphate kinase have also been proposed as T3SS effectors (Neeld et al., 2014; Burstein et al., 2015), the four classically cited *P. aeruginosa* T3SS effectors are ExoS, ExoU, ExoT, and ExoY (Figure 1). The latter two toxins are detected with a high prevalence in contrast to ExoS and ExoU, which have been reported to be mutually excluded in most studies (Feltman et al., 2001; Ozer et al., 2019). ExoS and ExoT are two homologous bifunctional enzymes with GTPase activating protein (GAP) activity in the N-terminal region and adenosine diphosphate ribosyl transferase (ADPRT) activity in the C-terminal region (reviewed by Barbieri and Sun, 2005). GAP activity, targeting an array of GTPases, reorganizes the actin cytoskeleton, leading to cell rounding and disruption of cell-to-cell adhesion while ADPRT activity, targeting the Ras protein, modifies the cytoskeleton (Garrity-Ryan et al., 2000; Garrity-Ryan et al., 2004; Sun and Barbieri, 2004). Furthermore, both GAP and ADPRT domains induce apoptosis (Kaufman et al., 2000; Shafikhani et al., 2008; Wood et al., 2015; Kaminski et al.,



2018). Although ExoS and ExoT possess similar domains, Shafikhani et al. (2008) suggest that the activity kinetic of these toxins could be different. ExoU is known to play a key role in the cytotoxic phenotype of *P. aeruginosa* through its phospholipase A2 (PLA2) activity (Sato et al., 2003; Schulert et al., 2003; Sato and Frank, 2004). This PLA2 activity, which produces lysophospholipids through the hydrolysis of membrane phospholipids, allows ExoU to disrupt the plasma membrane of host cells and cause rapid cell death (Phillips et al., 2003; Diaz and Hauser, 2010). ExoY is an actin-activated nucleotidyl cyclase that impacts the actin cytoskeleton (Yahr et al., 1998; Beckert et al., 2014; reviewed by Belyy et al., 2018). The actual clinical relevance of ExoY is still unclear, although a recent study showed a potential protective role of ExoY towards the cytotoxic effects of other *P. aeruginosa* virulence factors (Silistre et al., 2021).

Some effectors and other proteins implicated in T3SS need specific chaperones to facilitate their storage, conformational folding, and proper delivery to the secretion apparatus (see reviews Hauser, 2009; Horna and Ruiz, 2021).


The regulation of T3SS is complex and involves a variety of players. ExsA is the general transcriptional regulator binding promoter of T3SS genes, including its own promoter. Three additional proteins, ExsC, ExsD, and ExsE, control ExsA activity through a “catch and release” mechanism depending on whether *P. aeruginosa* is in contact or not with host cells (Hauser, 2009). Other players are also implicated in the regulation of T3SS transcription (For more details, see reviews Hauser, 2009; Horna and Ruiz, 2021).

## Implication of T3SS in the establishment of the IL-1 $\beta$ -mediated-inflammatory response to *P. aeruginosa*

The three translocon proteins of the needle tip, PcrV, PopB, and PopD, are required for *P. aeruginosa* to elicit rapid neutrophil recruitment into the airways, suggesting that T3SS affects the initial immune response of the host (Wangdi et al., 2010) to *P. aeruginosa* infection either directly, through the needle, or indirectly, through injection of exotoxins into the host cell. More specifically, T3SS can modulate the production of IL-1 $\beta$  whose signaling plays an important role in rapid neutrophil recruitment (Figure 2).

### NF- $\kappa$ B signaling pathway

The inducible transcription factor Nuclear Factor  $\kappa$ B (NF- $\kappa$ B) regulates the transcription of genes involved in the immune and inflammatory responses. The binding of Pathogen-Associated Molecular Patterns (PAMPs) or Damage-Associated Molecular Patterns (DAMPs) to specific cell Toll-Like Receptors (TLR) leads to the activation of NF- $\kappa$ B signaling which ultimately results in the expression of proinflammatory genes including cytokines, chemokines, and other inflammatory mediators (reviewed by Liu et al., 2017). This process plays a key role in the initiation of immune and inflammatory responses.



Several components of the T3SS structure have been reported to activate the NF- $\kappa$ B signaling pathway. The T3SS inner-rod protein PscI and needle protein PscF are recognized by TLR4 and TLR2 (Grandjean et al., 2017), which can induce NF- $\kappa$ B activation. More importantly, the needle-tip protein PcrV seems to be a potent inducer of the NF- $\kappa$ B-mediated proinflammatory response (Yu et al., 2020) since the addition of PcrV on biofilm-infected tissues induces an inflammatory response. The latter was characterized by an increased macrophage differentiation toward an M1 phenotype followed by activation of the M1-polarized macrophages and phagocytosis, which occurred *via* the mitogen-activated protein kinases (MAPKs) and NF- $\kappa$ B signaling pathways. The authors of this study also reported downregulation of *pcrV* gene expression during *P. aeruginosa* biofilm infection, which was associated with attenuated immune activation. Altogether, these findings suggest that *P. aeruginosa* regulates T3SS to promote biofilm and its persistence in the host.

In addition to the needle structure, the ExoU toxin can also activate the proinflammatory response through the NF- $\kappa$ B signaling pathway. ExoU is involved in the inflammatory response through the generation of lysophospholipids and free arachidonic acid (via its PLA2 activity on host membrane phospholipids), at local sites of *P. aeruginosa* infection (Saliba et al., 2005). Lysophospholipids can be acetylated to generate Platelet-Activating Factor (PAF), an inflammatory lipid mediator that initiates neutrophil recruitment. By binding to its receptor, PAFR, located on airway epithelial cells, PAF activates NF- $\kappa$ B and stimulates IL-8 secretion (Mallet de Lima et al., 2014). Additionally, free arachidonic acid is also involved in ExoU-induced inflammation through its conversion into eicosanoids, including prostaglandin (PGE<sub>2</sub> or PGI<sub>2</sub>) (Saliba et al., 2005), which are potent inducers of IL-6 and IL-8 production (Cho et al., 2014; Kawahara et al., 2015).

ExoY has been implicated in the decrease of IL-1 $\beta$  production and proinflammatory response both *in vitro* and in an animal model of lung infection by *P. aeruginosa* (Jeon et al., 2017; He et al., 2017; Kloth et al., 2018). Due to its adenylate cyclase activity, ExoY can reduce inflammasome-related responses by delaying the activation of NF- $\kappa$ B and caspase-1, resulting in a delayed inflammatory response (Jeon et al., 2017). Another study using a mouse model confirmed that ExoY can attenuate proinflammatory cytokine production by downregulating the activation of Transforming growth factor Activated Kinase 1 (TAK1), NF- $\kappa$ B, and MAPKs kinases (He et al., 2017).

## Inflammasome

NLRC4, as part of the Nod-like receptors (NLRs), allows host cells to sense pathogens and drive the innate immune response. PAMPs cause oligomerization and activation of

NLRC4 inflammasome resulting in caspase-1-dependent maturation of IL-1 $\beta$  and IL-18 cytokines and pyroptosis. This cytokine production results in the recruitment of inflammatory leukocytes, such as neutrophils and monocytes/macrophages to the site of infection to achieve *P. aeruginosa* killing (reviewed by Broz and Dixit, 2016).

The T3SS inner-rod protein PscI and the needle protein PscF are recognized by macrophages through the neuronal apoptosis inhibitory protein (NAIP) family, which then leads to NLRC4 inflammasome activation (Yang et al., 2013; Grandjean et al., 2017). The translocation apparatus, with PopD, PopB, and PcrV proteins, has also been reported to induce IL-1 $\beta$  production (Sutterwala et al., 2007; Franchi et al., 2007; Miao et al., 2008; Galle et al., 2012). Moreover, one study showed that the pore-forming activity of PopD-PopB results in potassium efflux and histone H3 modifications. The authors suggested that this phenomenon could activate the inflammasome and subsequent IL-1 $\beta$  maturation (Dortet et al., 2018). However, another study reported that PopB activates the NLRP3 inflammasome rather than the NLRC4 inflammasome, similarly to pore-forming toxins from other organisms (Grandjean et al., 2017).

A recent study demonstrated that recognition of *P. aeruginosa* T3SS leads to an NLRC4 inflammasome response, limiting the development of infection in wounds. In response to T3SS insertion into bone marrow-derived macrophages, CrkII interacts with the Abl tyrosine kinase and enables the subsequent phosphorylation cascade through Abl  $\rightarrow$  PKC $\delta$   $\rightarrow$  NLRC4, which is required for NLRC4 inflammasome assembly and activity (Mohamed et al., 2022). T3SS has also been reported to promote NLRC4 assembly and activation by inducing mitochondrial DNA and ROS release. Thus, the removal of damaged mitochondria generated after *P. aeruginosa* infection with functional T3SS blocks NLRC4 activation (Jabir et al., 2015). The flagellin FliC, which is a potent inducer of the NLRC4 inflammasome pathway, has also been reported to be translocated into host cells through T3SS and induces caspase-1 production (Ince et al., 2015).

Unlike the needle complex and the translocon, the *P. aeruginosa* T3SS effectors are implicated in NLRC4 dysregulation. ExoU was the first exotoxin shown to disrupt NLRC4 inflammasome activation, which transiently paralyzed the NLRC4 inflammasome (Sutterwala et al., 2007). Although the mechanisms involved still need to be elucidated, Hardy et al. (2022) recently showed an association between ExoU, host mitochondria, and caspase-1 activation. In addition to ExoU, ExoS has also been reported to regulate caspase-1-mediated IL-1 $\beta$  production by a mechanism dependent on its ADPRT activity (Galle et al., 2008). Recently, ExoT has been shown to inhibit NLRC4 inflammasome activation by disrupting CrkII/AbI interaction and blocking the phosphorylation cascade needed for NLRC4 assembly and function, resulting in a decrease in the inflammatory response (Mohamed et al., 2022).

Ince et al. (2015) showed that the  $\Delta$ STY mutant increases IL-1 release compared to the WT strain, suggesting a role of these

toxins in the modulation of the IL-1 production pathway, as cited above. Interestingly, this inhibition is lost in the WT strain with an overexpression of *FliC*, suggesting that the expression of the agonists and antagonists of inflammasome activation could be controlled during specific steps of infection. This hypothesis could explain why studies on the benefit of inflammasome activation in the process of *P. aeruginosa* clearance is discussed and give an interesting perspective for further studies. (Schultz et al., 2003; Sutterwala et al., 2007; Franchi et al., 2007; Cohen and Prince, 2013; Faure et al., 2014; Mohamed et al., 2022).

## Subversion of host immune response by the *P. aeruginosa* T3SS

Activation of the host immune response by T3SS results in the killing of *P. aeruginosa* but the pathogen can solve this dilemma by deploying exotoxins to disrupt the response initiated by the host, which helps *P. aeruginosa* to avoid its phagocytosis. Not only does *P. aeruginosa* protect itself from the host response, it also eliminates other pathogens such as *S. aureus* from the airways by manipulating the host immunity.

## Antiphagocytosis

Some of the exotoxins injected by the *P. aeruginosa* T3SS into host cytosol can intoxicate immune cells or inhibit *P. aeruginosa* phagocytosis to favor its persistence in host tissues. Due to its PLA2 activity that hydrolyzes membrane phospholipids and promotes necrosis, ExoU has been shown to intoxicate and kill neutrophils, as well as other phagocytic cells (Diaz et al., 2008; Diaz and Hauser, 2010). Moreover, both ExoS and ExoT trigger neutrophil apoptosis via a mechanism mediated by the ADPRT domain (Sun et al., 2012). Besides directly injuring phagocytic cells, the ADPRT activity of ExoS also inhibits *P. aeruginosa* phagocytic uptake by neutrophils and macrophages (Rangel et al., 2014). Additionally, the GAP domain of ExoT and ExoS can also reduce the ability of host cells to phagocytize *P. aeruginosa* (Garrity-Ryan et al., 2000; Barbieri and Sun, 2005).

Although *P. aeruginosa* can kill immune cells extracellularly and avoid its phagocytosis, it was reported to be engulfed by phagocytes in animal and cell culture models (Garai et al., 2019). Once in contact with immune and epithelial cells, *P. aeruginosa* must evade cellular defense mechanisms against pathogens to survive intracellularly. Studies have suggested a key role for ExoS in the intracellular persistence of *P. aeruginosa*. In macrophages, ExoS has been reported to modulate phagocytic vacuole escape via a mechanism controlled by MgtC and OprF and involving the GAP activity of ExoS (Garai et al., 2019). On the other hand, the ADPRT activity of ExoS promotes bacterial survival in

epithelial cells by establishing a protecting niche in the plasma membrane, i.e., a bleb niche where the bacteria replicate, and by abrogating vacuolar acidification (Angus et al., 2010; Heimer et al., 2013; Kroken et al., 2018). In neutrophils, ExoS and ExoT reduce bacterial killing by blocking the phagocytic NADPH-oxidase generating reactive oxygen species (Vareechon et al., 2017). However, although *P. aeruginosa* can invade cells and survive in the intracellular environment, the balance between extra and intracellular lifestyle during *P. aeruginosa* pathogenesis remains to be determined.

## Manipulation of sPLA2-IIA by *P. aeruginosa* to eradicate *Staphylococcus aureus*

During airway colonization of CF patients, *P. aeruginosa* not only uses its T3SS to subvert the host immune response to avoid its own eradication but also to eliminate *S. aureus* (Pernet et al., 2014). CF is an autosomal recessive lethal genetic disease characterized by altered bacterial clearance in the airways, leading to recurrent bacterial infections (Strausbaugh and Davis, 2007). However, the bacterial species varies with patient age, with *S. aureus* predominating during childhood and being progressively replaced by *P. aeruginosa* (Registre français de la mucoviscidose – Bilan des données 2020, 2022; Strausbaugh and Davis, 2007).

The secreted group IIA phospholipase A2 (sPLA2-IIA) is a potent bactericidal agent involved in the killing of several Gram-positive bacteria including *S. aureus* (Nevalainen et al., 2008). This enzyme is known to selectively kill Gram-positive bacteria by hydrolyzing its membrane phospholipids, leading to bacterial death (Foreman-Wykert et al., 1999) with minimal effects on host cells (Foreman-Wykert et al., 1999). Pernet et al. (2014) showed that infection of bronchial epithelial cells from CF patients by *P. aeruginosa* leads to the induction of sPLA2-IIA production, which in turn results in the killing of *S. aureus* from CF expectorations. However, none of the laboratory or clinical *S. aureus* strains tested were able to induce sPLA2-IIA expression in CF bronchial epithelial cells (Pernet et al., 2014). Induction of sPLA2-IIA expression by *P. aeruginosa* was attributed to the injection of ExoS into epithelial cells, which activates the Krüppel-like factor 2 (KLF2), a transcription factor known to exert anti-inflammatory activities in endothelial cells, monocytes and epithelial cells (O'Grady et al., 2006; Pernet et al., 2014). This mechanism differs from classical pathways known to modulate sPLA2-IIA expression in various cell systems (NF- $\kappa$ B, AP-1, and MAPK) (Menschikowski et al., 2006; Jensen et al., 2009). Nevertheless, whether ExoS induces sPLA2-IIA expression in pulmonary cells other than epithelial cells remains to be examined. This could include alveolar macrophages and endothelial cells, which were shown to be the primary cellular

source of sPLA2-IIA in lung tissue (Nevalainen et al., 2008; Hensbergen et al., 2020). Although the mechanism by which ExoS induces KLF2 expression in bronchial epithelial cells is still unclear, the ADPRT domain, and not the GAP domain, is involved in ExoS-induced sPLA2-IIA expression (Pernet et al., 2014). This study supports the notion that *P. aeruginosa* manipulates host cells by inducing their production of sPLA2-IIA which in turn kills *S. aureus* and promotes its establishment in CF airways.

In addition to this subversion mechanism, we have also shown that *P. aeruginosa* down-regulates the expression of the bactericidal antimicrobial peptide (AMP), cathelicidin LL-37, in bronchial epithelial cells via a mechanism involving the injection of ExoS into these cells (Abrial et al., 2017). This AMP is known to kill both laboratory and clinical strains of *P. aeruginosa* (Geitani et al., 2019). It was therefore concluded that such a process may allow *P. aeruginosa* to evade the host immune response and initiate infection. Further studies are necessary to identify the signaling pathways involved in LL-37 repression by ExoS.

## Summary

The T3SS is a major player in *P. aeruginosa* pathogenesis. Although T3SS is best known for stimulating the host immune response, this secretion system also allows *P. aeruginosa* to manipulate the inflammatory response to avoid its phagocytosis and to survive intracellularly. T3SS can also manipulate eukaryotic cells to eliminate other pathogens and become the dominant pathogen in certain host organs. Thus, T3SS interactions with host cells contribute to pathogen persistence and could negatively impact the outcome of infection.

The close interactions between T3SS and the immune system suggest that T3SS could be an interesting potential therapeutic target to combat *P. aeruginosa*, and some studies have proposed

## References

- Abrial, C., Da Sylva, J., and Touqui, L. (2017). "Regulation of cathelicidin LL-37 expression by *Pseudomonas aeruginosa* in human bronchial cystic fibrosis epithelial cells," in *American Thoracic Society International Conference Meetings Abstracts American Thoracic Society International Conference Meetings Abstracts*. American Journal of Respiratory and Critical Care Medicine 195, A1288.
- Angus, A. A., Evans, D. J., Barbieri, J. T., and Fleiszig, S. M. J. (2010). The ADP-ribosylation domain of *Pseudomonas aeruginosa* ExoS is required for membrane bleb niche formation and bacterial survival within epithelial cells. *Infect. Immun.* 78, 4500–4510. doi: 10.1128/IAI.00417-10
- Asadi Karam, M. R., Badmasti, F., Ahmadi, K., and Habibi, M. (2022). Vaccination of mice with hybrid protein containing exotoxin s and PcrV with adjuvants alum and MPL protects *Pseudomonas aeruginosa* infections. *Sci. Rep.* 12, 1325. doi: 10.1038/s41598-022-05157-3
- Audia, J. P., Lindsey, A. S., Housley, N. A., Ochoa, C. R., Zhou, C., Toba, M., et al. (2013). In the absence of effector proteins, the *Pseudomonas aeruginosa* type three secretion system needle tip complex contributes to lung injury and systemic inflammatory responses. *PLoS One* 8, e81792. doi: 10.1371/journal.pone.0081792
- Barbieri, J. T., and Sun, J. (2005). "*Pseudomonas aeruginosa* ExoS and ExoT," in *Reviews of physiology, biochemistry and pharmacology reviews of physiology,*

the use of certain components of T3SS as potential targets for antibacterial drugs and vaccines against *P. aeruginosa* infections (Naito et al., 2018; Moir et al., 2021; Asadi Karam et al., 2022).

## Author contributions

AJ, AS, and LT contributed to the writing of manuscript. All authors contributed to the article and approved the submitted version.

## Acknowledgments

We thank the Fondation Air Liquide for supporting our studies on *P. aeruginosa*. The authors warmly thank Nora Touqui for her precious and meticulous proofreading and English improvement of the present article.

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*biochemistry and pharmacology* (Berlin, Heidelberg: Springer), 79–92. doi: 10.1007/s10254-004-0031-7

Beckert, U., Wolter, S., Hartwig, C., Bähre, H., Kaefer, V., Ladant, D., et al. (2014). ExoY from *Pseudomonas aeruginosa* is a nucleotidyl cyclase with preference for cGMP and cUMP formation. *Biochem. Biophys. Res. Commun.* 450, 870–874. doi: 10.1016/j.bbrc.2014.06.088

Belyy, A., Mechold, U., Renault, L., and Ladant, D. (2018). ExoY, an actin-activated nucleotidyl cyclase toxin from *P. aeruginosa*: A minireview. *Toxicon* 149, 65–71. doi: 10.1016/j.toxicon.2017.12.046

Broz, P., and Dixit, V. M. (2016). Inflammasomes: mechanism of assembly, regulation and signalling. *Nat. Rev. Immunol.* 16, 407–420. doi: 10.1038/nri.2016.58

Burstein, D., Satanower, S., Simovitch, M., Belnik, Y., Zehavi, M., Yerushalmi, G., et al. (2015). Novel type III effectors in *Pseudomonas aeruginosa*. *mBio* 6, e00161. doi: 10.1128/mBio.00161-15

Cho, J.-S., Han, I.-H., Lee, H. R., and Lee, H.-M. (2014). Prostaglandin E2 induces IL-6 and IL-8 production by the EP Receptors/Akt/NF-κB pathways in nasal polyp-derived fibroblasts. *Allergy Asthma Immunol. Res.* 6, 449–457. doi: 10.4168/aa.2014.6.5.449

- Cohen, T. S., and Prince, A. S. (2013). Activation of inflammasome signaling mediates pathology of acute *P. aeruginosa* pneumonia. *J. Clin. Invest.* 123, 1630–1637. doi: 10.1172/JCI66142
- Deng, W., Marshall, N. C., Rowland, J. L., McCoy, J. M., Worrall, L. J., Santos, A. S., et al. (2017). Assembly, structure, function and regulation of type III secretion systems. *Nat. Rev. Microbiol.* 15, 323–337. doi: 10.1038/nrmicro.2017.20
- Diaz, M. H., and Hauser, A. R. (2010). *Pseudomonas aeruginosa* cytotoxin ExoU is injected into phagocytic cells during acute pneumonia. *Infect. Immun.* 78, 1447–1456. doi: 10.1128/IAI.01134-09
- Diaz, M. H., Shaver, C. M., King, J. D., Musunuri, S., Kazzaz, J. A., and Hauser, A. R. (2008). *Pseudomonas aeruginosa* induces localized immunosuppression during pneumonia. *Infect. Immun.* 76, 4414–4421. doi: 10.1128/IAI.00012-08
- Dortet, L., Lombardi, C., Cretin, F., Dessen, A., and Filloux, A. (2018). Pore-forming activity of the *Pseudomonas aeruginosa* type III secretion system translocon alters the host epigenome. *Nat. Microbiol.* 3, 378–386. doi: 10.1038/s41564-018-0109-7
- Faure, E., Mear, J.-B., Faure, K., Normand, S., Couturier-Maillard, A., Grandjean, T., et al. (2014). *Pseudomonas aeruginosa* type-3 secretion system dampens host defense by exploiting the NLRCA-coupled inflammasome. *Am. J. Respir. Crit. Care Med.* 189, 799–811. doi: 10.1164/rccm.201307-1358OC
- Feltman, H., Schulert, G., Khan, S., Jain, M., Peterson, L., and Hauser, A. R. (2001). Prevalence of type III secretion genes in clinical and environmental isolates of *Pseudomonas aeruginosa*. *Microbiology* 147, 2659–2669. doi: 10.1099/00221287-147-10-2659
- Foreman-Wykert, A. K., Weinrauch, Y., Elsbach, P., and Weiss, J. (1999). Cell-wall determinants of the bactericidal action of group IIA phospholipase A2 against gram-positive bacteria. *J. Clin. Invest.* 103, 715–721. doi: 10.1172/JCI5468
- Franchi, L., Stoolman, J., Kanneganti, T.-D., Verma, A., Ramphal, R., and Núñez, G. (2007). Critical role for ipaf in *Pseudomonas aeruginosa*-induced caspase-1 activation. *Eur. J. Immunol.* 37, 3030–3039. doi: 10.1002/eji.200737532
- Galle, M., Jin, S., Bogaert, P., Haegman, M., Vandenebelee, P., and Beyaert, R. (2012). The *Pseudomonas aeruginosa* type III secretion system has an exotoxin S/T/Y independent pathogenic role during acute lung infection. *PLoS One* 7, e41547. doi: 10.1371/journal.pone.0041547
- Galle, M., Schotte, P., Haegman, M., Wullaert, A., Yang, H. J., Jin, S., et al. (2008). The *Pseudomonas aeruginosa* type III secretion system plays a dual role in the regulation of caspase-1 mediated IL-1 $\beta$  maturation. *J. Cell Mol. Med.* 12, 1767–1776. doi: 10.1111/j.1582-4934.2007.00190.x
- Garai, P., Berry, L., Moussouni, M., Blevess, S., and Blanc-Potard, A.-B. (2019). Killing from the inside: Intracellular role of T3SS in the fate of *Pseudomonas aeruginosa* within macrophages revealed by mgtC and oprF mutants. *PLoS Pathog.* 15, e1007812. doi: 10.1371/journal.ppat.1007812
- Garrity-Ryan, L., Kazmierczak, B., Kowal, R., Comolli, J., Hauser, A., and Engel, J. N. (2000). The arginine finger domain of ExoT contributes to actin cytoskeleton disruption and inhibition of internalization of *Pseudomonas aeruginosa* by epithelial cells and macrophages. *Infect. Immun.* 68, 7100–7113. doi: 10.1128/IAI.68.12.7100-7113.2000
- Garrity-Ryan, L., Shafikhani, S., Balachandran, P., Nguyen, L., Oza, J., Jakobsen, T., et al. (2004). The ADP ribosyltransferase domain of *Pseudomonas aeruginosa* ExoT contributes to its biological activities. *Infect. Immun.* 72, 546–558. doi: 10.1128/IAI.72.1.546-558.2004
- Geitani, R., Ayoub Moubareck, C., Touqui, L., and Karam Sarkis, D. (2019). Cationic antimicrobial peptides: alternatives and/or adjuvants to antibiotics active against methicillin-resistant *Staphylococcus aureus* and multidrug-resistant *Pseudomonas aeruginosa*. *BMC Microbiol.* 19, 54. doi: 10.1186/s12866-019-1416-8
- Gonçalves-de-Albuquerque, C. F., Silva, A. R., Burth, P., Rocco, P. R. M., Castro-Faria, M. V., and Castro-Faria-Neto, H. C. (2016). Possible mechanisms of *Pseudomonas aeruginosa*-associated lung disease. *Int. J. Med. Microbiol.* 306, 20–28. doi: 10.1016/j.ijmm.2015.11.001
- Goure, J., Pastor, A., Faudry, E., Chabert, J., Dessen, A., and Attree, I. (2004). The V antigen of *Pseudomonas aeruginosa* is required for assembly of the functional PopB/PopD translocation pore in host cell membranes. *Infection Immun.* 72, 4741–4750. doi: 10.1128/IAI.72.8.4741-4750.2004
- Grandjean, T., Boucher, A., Thepaut, M., Monlezun, L., Guery, B., Faudry, E., et al. (2017). The human NAIIP-NLRCA-inflammasome senses the *Pseudomonas aeruginosa* T3SS inner-rod protein. *Int. Immunol.* 29, 377–384. doi: 10.1093/intimm/dxx047
- Hardy, K. S., Tuckey, A. N., Housley, N. A., Andrews, J., Patel, M., Al-Mehdi, A.-B., et al. (2022). The *Pseudomonas aeruginosa* type III secretion system coenzyme effector ExoU induces mitochondrial damage in a murine bone marrow-derived macrophage infection model. *Infect. Immun.* 90, e0047021. doi: 10.1128/IAI.00470-21
- Hauser, A. R. (2009). The type III secretion system of *Pseudomonas aeruginosa*: infection by injection. *Nat. Rev. Microbiol.* 7, 654–665. doi: 10.1038/nrmicro2199
- Heimer, S. R., Evans, D. J., Stern, M. E., Barbieri, J. T., Yahr, T., and Fleiszig, S. M. J. (2013). *Pseudomonas aeruginosa* utilizes the type III secreted toxin ExoS to avoid acidified compartments within epithelial cells. *PLoS One* 8, e73111. doi: 10.1371/journal.pone.0073111
- Hensbergen, V. P., Wu, Y., van Sorge, N. M., and Touqui, L. (2020). Type IIA secreted phospholipase A2 in host defense against bacterial infections. *Trends Immunol.* 41, 313–326. doi: 10.1016/j.it.2020.02.003
- He, C., Zhou, Y., Liu, F., Liu, H., Tan, H., Jin, S., et al. (2017). Bacterial nucleotidyl cyclase inhibits the host innate immune response by suppressing TAK1 activation. *Infect. Immun.* 85, e00239–e00217. doi: 10.1128/IAI.00239-17
- Hirsch, E. B., and Tam, V. H. (2010). Impact of multidrug-resistant *Pseudomonas aeruginosa* infection on patient outcomes. *Expert Rev. Pharmacoecon. Outcomes Res.* 10, 441–451. doi: 10.1586/erp.10.49
- Horna, G., and Ruiz, J. (2021). Type 3 secretion system of *Pseudomonas aeruginosa*. *Microbiol. Res.* 246, 126719. doi: 10.1016/j.micres.2021.126719
- Ince, D., Sutterwala, F. S., and Yahr, T. L. (2015). Secretion of flagellar proteins by the *Pseudomonas aeruginosa* type III secretion-injectisome system. *J. Bacteriol.* 197, 2003–2011. doi: 10.1128/JB.00030-15
- Jabir, M. S., Hopkins, L., Ritchie, N. D., Ullah, I., Bayes, H. K., Li, D., et al. (2015). Mitochondrial damage contributes to *Pseudomonas aeruginosa* activation of the inflammasome and is downregulated by autophagy. *Autophagy* 11, 166–182. doi: 10.4161/15548627.2014.981915
- Jensen, M. D., Sheng, W., Simonyi, A., Johnson, G. S., Sun, A. Y., and Sun, G. Y. (2009). Involvement of oxidative pathways in cytokine-induced secretory phospholipase A2-IIA in astrocytes. *Neurochem. Int.* 55, 362–368. doi: 10.1016/j.neuint.2009.04.002
- Jeon, J., Kim, Y.-J., Shin, H., and Ha, U.-H. (2017). T3SS effector ExoY reduces inflammasome-related responses by suppressing bacterial motility and delaying activation of NF- $\kappa$ B and caspase-1. *FEBS J.* 284, 3392–3403. doi: 10.1111/febs.14199
- Juan, C., Peña, C., and Oliver, A. (2017). Host and pathogen biomarkers for severe *Pseudomonas aeruginosa* infections. *J. Infect. Dis.* 215, S44–S51. doi: 10.1093/infdis/jiw299
- Kaminski, A., Gupta, K. H., Goldufsky, J. W., Lee, H. W., Gupta, V., and Shafikhani, S. H. (2018). *Pseudomonas aeruginosa* ExoS induces intrinsic apoptosis in target host cells in a manner that is dependent on its GAP domain activity. *Sci. Rep.* 8, 14047. doi: 10.1038/s41598-018-32491-2
- Kaufman, M. R., Jia, J., Zeng, L., Ha, U., Chow, M., and Jin, S. (2000). *Pseudomonas aeruginosa* mediated apoptosis requires the ADP-ribosylating activity of exoS. *Microbiol. (Reading)* 146 (Pt 10), 2531–2541. doi: 10.1099/00221287-146-10-2531
- Kawahara, K., Hohjoh, H., Inazumi, T., Tsuchiya, S., and Sugimoto, Y. (2015). Prostaglandin E2-induced inflammation: Relevance of prostaglandin e receptors. *Biochim. Biophys. Acta (BBA) - Mol. Cell Biol. Lipids* 1851, 414–421. doi: 10.1016/j.bbalip.2014.07.008
- Kloth, C., Schirmer, B., Munder, A., Stelzer, T., Rothschild, J., and Seifert, R. (2018). The role of *Pseudomonas aeruginosa* exoY in an acute mouse lung infection model. *Toxins (Basel)* 10, 185. doi: 10.3390/toxins10050185
- Kroken, A. R., Chen, C. K., Evans, D. J., Yahr, T. L., and Fleiszig, S. M. J. (2018). The impact of ExoS on *Pseudomonas aeruginosa* internalization by epithelial cells is independent of fleQ and correlates with bistability of type three secretion system gene expression. *mBio* 9, e00668–e00618. doi: 10.1128/mBio.00668-18
- Liu, T., Zhang, L., Joo, D., and Sun, S.-C. (2017). NF- $\kappa$ B signaling in inflammation. *Sig Transduct Target Ther.* 2, 1–9. doi: 10.1038/sigtrans.2017.23
- Lombardi, C., Tolchard, J., Bouillot, S., Signor, L., Gebus, C., Liebl, D., et al. (2019). Structural and functional characterization of the type three secretion system (T3SS) needle of *Pseudomonas aeruginosa*. *Front. Microbiol.* 10. doi: 10.3389/fmicb.2019.00573
- Malhotra, S., Hayes, D., and Wozniak, D. J. (2019). Cystic fibrosis and *Pseudomonas aeruginosa*: the host-microbe interface. *Clin. Microbiol. Rev.* 32, e00138–e00118. doi: 10.1128/CMR.00138-18
- Mallet de Lima, C. D., da Conceição Costa, J., de Oliveira Lima Santos, S. A., Carvalho, S., de Carvalho, L., Albano, R. M., et al. (2014). Central role of PAFR signalling in ExoU-induced NF- $\kappa$ B activation. *Cell Microbiol.* 16, 1244–1254. doi: 10.1111/cmi.12280
- Menschikowski, M., Hagelgans, A., and Siegert, G. (2006). Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? *Prostaglandins Other Lipid Mediat.* 79, 1–33. doi: 10.1016/j.prostaglandins.2005.10.005
- Miao, E. A., Ernst, R. K., Dors, M., Mao, D. P., and Adere, A. (2008). *Pseudomonas aeruginosa* activates caspase 1 through ipaf. *Proc. Natl. Acad. Sci. U.S.A.* 105, 2562–2567. doi: 10.1073/pnas.0712183105
- Mohamed, M. F., Gupta, K., Goldufsky, J. W., Roy, R., Callaghan, L. T., Wetzel, D. M., et al. (2022). CrkII/Abl phosphorylation cascade is critical for NLRCA inflammasome activity and is blocked by *Pseudomonas aeruginosa* ExoT. *Nat. Commun.* 13, 1295. doi: 10.1038/s41467-022-28967-5



- Moir, D. T., Opperman, T. J., Aron, Z. D., and Bowlin, T. L. (2021). Adjunctive therapy for multidrug-resistant bacterial infections: type III secretion system and efflux inhibitors. *Drug Discovery Today* 9, 2173–2181. doi: 10.1016/j.drudis.2021.03.031
- Mulani, M. S., Kamble, E. E., Kumkar, S. N., Tawre, M. S., and Pardesi, K. R. (2019). Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: A review. *Front. Microbiol.* 10. doi: 10.3389/fmicb.2019.00539
- Naito, Y., Hamaoka, S., Kinoshita, M., Kainuma, A., Shimizu, M., Katoh, H., et al. (2018). The protective effects of nasal PcrV-CpG oligonucleotide vaccination against *Pseudomonas aeruginosa* pneumonia. *Microbiol. Immunol.* 62, 774–785. doi: 10.1111/1348-0421.12658
- Neeld, D., Jin, Y., Bichsel, C., Jia, J., Guo, J., Bai, F., et al. (2014). *Pseudomonas aeruginosa* injects NDK into host cells through a type III secretion system. *Microbiol. (Reading)* 160, 1417–1426. doi: 10.1099/mic.0.078139-0
- Nevalainen, T. J., Graham, G. G., and Scott, K. F. (2008). Antibacterial actions of secreted phospholipases A2. review. *Biochim. Biophys. Acta* 1781, 1–9. doi: 10.1016/j.bbali.2007.12.001
- Notti, R. Q., and Stebbins, C. E. (2016). The structure and function of type III secretion systems. *Microbiol. Spectr.* 4 (1). doi: 10.1128/microbiolspec.VMBF-0004-2015
- O'Grady, E. P., Mulcahy, H., O'Callaghan, J., Adams, C., and O'Gara, F. (2006). *Pseudomonas aeruginosa* infection of airway epithelial cells modulates expression of kruppel-like factors 2 and 6 via RsmA-mediated regulation of type III exoenzymes  $\epsilon$  and  $\gamma$ . *Infect. Immun.* 74, 5893–5902. doi: 10.1128/IAI.00489-06
- Ozer, E. A., Nnah, E., Didelot, X., Whitaker, R. J., and Hauser, A. R. (2019). The population structure of *Pseudomonas aeruginosa* is characterized by genetic isolation of exoU+ and exoS+ lineages. *Genome Biol. Evol.* 11, 1780–1796. doi: 10.1093/gbe/evz119
- Pernet, E., Guillemot, L., Burgel, P.-R., Martin, C., Lambeau, G., Sermet-Gaudelus, I., et al. (2014). *Pseudomonas aeruginosa* eradicates *Staphylococcus aureus* by manipulating the host immunity. *Nat. Commun.* 5, 5105. doi: 10.1038/ncomms6105
- Phillips, R. M., Six, D. A., Dennis, E. A., and Ghosh, P. (2003). *In vivo* phospholipase activity of the *Pseudomonas aeruginosa* cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors. *J. Biol. Chem.* 278, 41326–41332. doi: 10.1074/jbc.M302472200
- Qin, S., Xiao, W., Zhou, C., Pu, Q., Deng, X., Lan, L., et al. (2022). *Pseudomonas aeruginosa*: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. *Sig Transduct Target Ther.* 7, 1–27. doi: 10.1038/s41392-022-01056-1
- Rangel, S. M., Logan, L. K., and Hauser, A. R. (2014). The ADP-ribosyltransferase domain of the effector protein ExoS inhibits phagocytosis of *Pseudomonas aeruginosa* during pneumonia. *mBio* 5, e01080–e01014. doi: 10.1128/mBio.01080-14
- Registre français de la mucoviscidose – Bilan des données 2020 (2022). Vaincre la Mucoviscidose. Available at: [https://www.vaincrelamuco.org/sites/default/files/registre\\_francais\\_de\\_la\\_mucoviscidose\\_bilan\\_2020.pdf](https://www.vaincrelamuco.org/sites/default/files/registre_francais_de_la_mucoviscidose_bilan_2020.pdf)
- Romano, F. B., Rossi, K. C., Savva, C. G., Holzenburg, A., Clerico, E. M., and Heuck, A. P. (2011). Efficient isolation of *Pseudomonas aeruginosa* type III secretion translocators and assembly of heteromeric transmembrane pores in model membranes. *Biochemistry* 50, 7117–7131. doi: 10.1021/bi200905x
- Saliba, A. M., Nascimento, D. O., Silva, M. C. A., Assis, M. C., Gayer, C. R. M., Raymond, B., et al. (2005). Eicosanoid-mediated proinflammatory activity of *Pseudomonas aeruginosa* ExoU. *Cell. Microbiol.* 7, 1811–1822. doi: 10.1111/j.1462-5822.2005.00635.x
- Sato, H., and Frank, D. W. (2004). ExoU is a potent intracellular phospholipase. *Mol. Microbiol.* 53, 1279–1290. doi: 10.1111/j.1365-2958.2004.04194.x
- Sato, H., Frank, D. W., Hillard, C. J., Feix, J. B., Pankhaniya, R. R., Moriyama, K., et al. (2003). The mechanism of action of the *Pseudomonas aeruginosa*-encoded type III cytotoxin, ExoU. *EMBO J.* 22, 2959–2969. doi: 10.1093/emboj/cdg290
- Schulert, G. S., Feltman, H., Rabin, S. D. P., Martin, C. G., Battle, S. E., Rello, J., et al. (2003). Secretion of the toxin ExoU is a marker for highly virulent *Pseudomonas aeruginosa* isolates obtained from patients with hospital-acquired pneumonia. *J. Infect. Dis.* 188, 1695–1706. doi: 10.1086/379372
- Schultz, M. J., Knapp, S., Florquin, S., Pater, J., Takeda, K., Akira, S., et al. (2003). Interleukin-18 impairs the pulmonary host response to *Pseudomonas aeruginosa*. *Infect. Immun.* 71, 1630–1634. doi: 10.1128/IAI.71.4.1630-1634.2003
- Shafikhani, S. H., Morales, C., and Engel, J. (2008). The *Pseudomonas aeruginosa* type III secreted toxin ExoT is necessary and sufficient to induce apoptosis in epithelial cells. *Cell. Microbiol.* 10, 994–1007. doi: 10.1111/j.1462-5822.2007.01102.x
- Silistre, H., Raoux-Barbot, D., Mancinelli, F., Sangouard, F., Dupin, A., Belyy, A., et al. (2021). Prevalence of exoY activity in *Pseudomonas aeruginosa* reference panel strains and impact on cytotoxicity in epithelial cells. *Front. Microbiol.* 12. doi: 10.3389/fmicb.2021.666097
- Strausbaugh, S. D., and Davis, P. B. (2007). Cystic fibrosis: a review of epidemiology and pathobiology. *Clinics Chest Med.* 28, 279–288. doi: 10.1016/j.ccm.2007.02.011
- Sun, J., and Barbieri, J. T. (2004). ExoS rho GTPase-activating protein activity stimulates reorganization of the actin cytoskeleton through rho GTPase guanine nucleotide disassociation inhibitor. *J. Biol. Chem.* 279, 42936–42944. doi: 10.1074/jbc.M406493200
- Sun, Y., Karmakar, M., Taylor, P. R., Rietsch, A., and Pearlman, E. (2012). ExoS and ExoT ADP-ribosyltransferase activities mediate *Pseudomonas aeruginosa* keratitis by promoting neutrophil apoptosis and bacterial survival. *J. Immunol.* 188, 1884–1895. doi: 10.4049/jimmunol.1102148
- Sutterwala, F. S., Mijares, L. A., Li, L., Ogura, Y., Kazmierczak, B. I., and Flavell, R. A. (2007). Immune recognition of *Pseudomonas aeruginosa* mediated by the IPAF/NLRC4 inflammasome. *J. Exp. Med.* 204, 3235–3245. doi: 10.1084/jem.20071239
- Vareechon, C., Zmina, S. E., Karmakar, M., Pearlman, E., and Rietsch, A. (2017). *Pseudomonas aeruginosa* effector ExoS inhibits ROS production in human neutrophils. *Cell Host Microbe* 21, 611–618.e5. doi: 10.1016/j.chom.2017.04.001
- Wangdi, T., Mijares, L. A., and Kazmierczak, B. I. (2010). *In vivo* discrimination of type 3 secretion system-positive and -negative *Pseudomonas aeruginosa* via a caspase-1-dependent pathway. *Infection Immun.* 78, 4744–4753. doi: 10.1128/IAI.00744-10
- Wood, S. J., Goldufsky, J. W., Bello, D., Masood, S., and Shafikhani, S. H. (2015). *Pseudomonas aeruginosa* ExoT induces mitochondrial apoptosis in target host cells in a manner that depends on its GTPase-activating protein (GAP) domain activity. *J. Biol. Chem.* 290, 29063–29073. doi: 10.1074/jbc.M115.689950
- Yahr, T. L., Vallis, A. J., Hancock, M. K., Barbieri, J. T., and Frank, D. W. (1998). ExoY, an adenylate cyclase secreted by the *Pseudomonas aeruginosa* type III system. *Proc. Natl. Acad. Sci.* 95, 13899–13904. doi: 10.1073/pnas.95.23.13899
- Yang, J., Zhao, Y., Shi, J., and Shao, F. (2013). Human NAIP and mouse NAIP1 recognize bacterial type III secretion needle protein for inflammasome activation. *Proc. Natl. Acad. Sci.* 110, 14408–14413. doi: 10.1073/pnas.1306376110
- Yu, H., Xiong, J., Qiu, J., He, X., Sheng, H., Dai, Q., et al. (2020). Type III secretion protein, PcrV, impairs *Pseudomonas aeruginosa* biofilm formation by increasing M1 macrophage-mediated anti-bacterial activities. *Front. Microbiol.* 11. doi: 10.3389/fmicb.2020.01971